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Abstract: Vitamin D insufficiency/deficiency has been observed worldwide at all stages of 
life. It has been characterized as a public health problem, since low concentrations of this 
vitamin have been linked to the pathogenesis of several chronic diseases. Several studies 
have suggested that vitamin D is involved in cardiovascular diseases and have provided 
evidence that it has a role in reducing cardiovascular disease risk. It may be involved in 
regulation of gene expression through the presence of vitamin D receptors in various cells, 
regulation of blood pressure (through renin-angiotensin system), and modulation of cell 
growth and proliferation including vascular smooth muscle cells and cardiomyocytes. 
Identifying correct mechanisms and relationships between vitamin D and such diseases 
could be important in relation to patient care and healthcare policies. 
Keywords: vitamin D; cardiovascular disease; hypertension 
 
1. Introduction  
The main function of vitamin D relates to the development and maintenance of bone tissue. It is 
responsible for maintaining calcium and phosphorus homeostasis. Vitamin D insufficiency/deficiency 
has been observed worldwide at all stages of life. It has been characterized as a public health problem, 
since low concentrations of this vitamin has been linked to the pathogenesis of several chronic diseases 
with cardiovascular risk factors, such as hypertension, heart failure, atherosclerosis and peripheral 
arterial disease [1-3]. Following the discovery of the presence of vitamin D receptors (VDR) in many 
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cells, including cardiomyocytes [4], vascular smooth muscle cells (VSMC) [5] and endothelium [6], 
several mechanisms have been proposed to explain the relationship between vitamin D and the 
development of cardiovascular disease. Such mechanisms include involvement of vitamin D in the 
angiotensin-renin system [7] and proliferation and growth of VSMC [8].  
 
2. Physiology of Vitamin D 
Vitamin D is found as ergocalciferol (vitamin D2) produced by plant and as cholecalciferol (vitamin 
D3) produced by animal tissue. It is also produced by exposure to ultraviolet-B (290 to 310 nm) in 7-
dehydrocholesterol, which is present in human skin [9]. It has been estimated that 80-90% of vitamin 
D is acquired by means of cutaneous synthesis and the remainder through the diet [10]. Vitamin D 
prohormone is biologically inactive, and it becomes active through conversion to its major form 25-
hydroxyvitamin D (25(OH)D) in the liver: this metabolite is used to classify vitamin D status. 
Following this, the hormonal form of vitamin D (1,25-dihydroxyvitamin D [1,25(OH)2D3] or calcitriol) 
is produced in other tissues like prostate, breast, colon and especially the kidneys, through 1-alpha-
hydroxylase [9,10]. This metabolite production is controlled by the serum parathyroid hormone (PTH), 
calcium and phosphorus concentrations.  
The effects of 1,25(OH)2D3 are mediated by VDR, which are present in many cells. At the nucleus 
of the target cells, 1,25(OH)2D3 associated with VDR binds to the retinoic X receptor (RXR), thereby 
forming heterodimers. These work on vitamin D response elements, hence initiating the cascade of 
molecular interactions that will modulate the transcription of the specific gene [11]. Thus, exceedingly 
low concentrations of 25(OH)D can result in failure of this metabolic cascade and alter   
gene expression. 
Individuals’ vitamin D levels or their nutritional status regarding vitamin D are measured according 
to the plasma levels of 25(OH)D. The biologically active form of vitamin D, (1,25(OH)2D3), is 
unsuitable for this purpose for reasons such as: a) the rigid maintenance of plasma levels of 
1,25(OH)2D3 at normal concentrations, even with low plasma concentrations of 25(OH)D (except in 
cases of chronic kidney disease and in the presence of high fibroblast growth factor-23 
concentrations); b) plasma 25(OH)D levels are approximately 100-times greater than those of 
1,25(OH)2D3; and c) hydroxylation of 25(OH)D to 1,25(OH)2D3 occurs in various tissues, thereby 
covering local needs [12]. 
In 2005, Hollis [13] considered that the optimal level of vitamin D would be that required to 
maintain parathyroid hormone (PTH) at appropriate levels. It is known that vitamin D deficiency leads 
to decreased serum calcium, which consequently stimulates the parathyroid glands to release PTH, 
thereby increasing renal reabsorption and bone calcium levels. In this regard, several studies have 
found a plateau of calcium absorption and adequate PTH levels, with 25(OH)D levels close to 30 
ng/mL (75 nmol/L) [14-18]. However, the adequate levels of 25(OH)D for non-calcemic disorders has 
still not been established.  
2.1. Sources of Vitamin D 
Factors such as latitude, season and time of day influence the cutaneous synthesis of vitamin D. 
During the summer, 7-dehydrocholesterol in the skin is more efficiently converted to previtamin D. Nutrients 2010, 2                                       
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Cutaneous synthesis of vitamin D is higher in low-latitude regions because of greater exposure to 
sunlight [19]. The use of sunscreen, the amount of melanin in the skin, types of clothing and high 
levels of air pollution may reduce skin exposure to UVB and result in decreased synthesis of vitamin 
D. Another important factor leading to hypovitaminosis D is changes in lifestyle, such as reduction of 
outdoor activities. 
There are limited natural dietary sources of vitamin D. Not all countries have regulations requiring 
food fortification, and this leads to low consumption. Table 1 demonstrates the vitamin D content in 
selected foods. A recent review [20] showed the dietary requirements for adequate vitamin D 
nutritional status. For example, for 97.5% of the population aged 20–40 years, a mean intake during 
the winter of 8.7 µg/d would be needed in order to achieve 25(OH)D serum level greater than 25 
nmol/L, and 41.1 µg/d for a 25(OH)D level of 80 nmol/L. The same dietary requirements have been 
observed among the elderly [21]. 
However, studies have demonstrated that several populations do not attain these dietary intake 
levels [22,23]. 
Table 1. Vitamin D2 and D3 content in selected foods, adapted from the USDA national 
nutrient database for standard reference, Release 22. 
Foods (common portion sizes)  Vitamin D content (μg) 
  Vitamin D2 Vitamin  D3 
Salmon, cooked (155g)  0.0  36.1 
Tuna, canned in oil (85g)  0.0  5.7 
Sardines (24g)  0.0  4.8 
Liver, beef cooked (85g)  0.0  1.0 
Top sirloin, beef cooked broiled (85g)  0.0  0.2 
Whole milk with vitamin D fortification (244g)  0.0  1.3 
Whole milk, without vitamin D (244g)  0.0  0.1 
Butter (5g)   0.0  1.5 
Mushrooms, portabella, grilled(121g)  0.3  0.0 
Mushrooms, portabella, grilled, exposed to UV 
light (121g) 
13.1 1.0 
Mushrooms, shiitake, cooked (72g)  0.7  0.1 
Vegetables (kale, broccoli, spinach, tomato, 
carrots and lettuce) (100g) 
0.0 0.0 
3. Epidemiological and Observational Evidence 
Cardiovascular diseases are the leading cause of death worldwide. According to the World Health 
Organization (WHO), these diseases affect 17.1 million people around the world and deaths occur Nutrients 2010, 2                                       
 
 
429
predominantly in low and middle-income countries, almost equally in men and women. A reduction of 
2 to 3 mmHg in systolic blood pressure is associated with a reduction of 10 to 15% in mortality from 
cardiovascular disease [24]. 
Recently, Giovannucci et al. [25] assessed the association between serum 25(OH)D and risk of 
coronary disease among men who participated in the Health Professionals Follow-up Study. Men with 
vitamin D deficiency (≤15 ng/ml or 37 nmol/L) were at significantly increased risk of developing 
myocardial infarction, compared with those with sufficient levels of vitamin D (≥30 ng/mL or 75 
nmol/L) (RR 2.09; 95% CI: 1.24–3.54).  
Analyzing the population of NHANES III, Melamed et al. [26] observed that the prevalence ratio of 
peripheral arterial disease for the lowest 25(OH)D quartile, compared with the highest quartile (<44.5 
and ≥73.8 nmol/L, respectively) was 1.80 (95% CI: 1.19–2.74). A similar situation has been observed 
in other studies [27,28] on the population of NHANES III, evaluating the associations between serum 
25(OH)D and coronary heart disease, heart failure, stroke and peripheral arterial disease.  
Comparing vitamin D status among more than 3000 subjects, over a seven-year follow-up period, 
Pilz et al. [29] found that patients with severe vitamin D deficiency [25(OH)D < 25 nmol/L] had a risk 
of dying from heart failure or sudden cardiac death that was three to five times greater than among 
patients with optimal levels of vitamin D [25(OH)D ≥ 75 nmol/L]. In patients who had already had 
heart failure, low serum calcitriol concentrations were associated with critical end-stage   
outcomes [30].  
Evaluating data from InCHIANTI, a prospective cohort study on aging, it was observed that 
participants who were in the lowest quartile of serum 25(OH)D (≤ 26.25 nmol/L) were at higher risk of all-
cause mortality (HR 2.11, 95% CI: 1.22–3.64, p = 0.007) and mortality from cardiovascular disease (HR 
2.64, 95% CI: 1.14–4.79, p = 0.02), compared with those in the highest quartile (≥66.25 nmol/L) [31]. 
Among adolescents [32], it was also demonstrated that low 25(OH)D levels were strongly inversely 
associated with cardiometabolic risk factors (systolic blood pressure and plasma glucose 
concentrations). 
The involvement of vitamin D insufficiency with hypertension has also been demonstrated. 
Investigating the population over the age of 20 years who participated in NHANES III, Scragg et al. 
[3] found systolic and diastolic pressures that were respectively 3.0 and 1.6 mmHg lower in highest 
quintile of 25(OH)D (≥ 85.7 nmol/L), compared with the lowest quintile of vitamin D (25(OH)D ≤  
40 nmol/L). In the Nurses Health Study and the Healthy Professional Follow-up Study, the negative 
relationship between serum levels of vitamin D and hypertension was also demonstrated [33]. After 
four years of follow-up, the relative risk for men with low levels of serum 25(OH)D to develop 
hypertension was 6.13 (95% CI: 1.00–37.80), while for women it was 2.67 (95% CI: 1.05–6.97). After 
eight years of follow-up, the relative risk for men was 3.53 (95% CI: 1.02–12.3) and for women, 1.7 
(95% CI: 0.92–3.16).  
4. Proposed Mechanisms for Vitamin D in Cardiovascular Disease 
The mechanisms underlying the role of  vitamin D in the prevention of heart disease remain 
incompletely explained. However, the mechanisms hypothesized involve the presence of VDR in 
various cells and its possible modulation of the expression of several genes. 1,25(OH)2D3 may Nutrients 2010, 2                                       
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interfere in the cascade of reactions and consequent functional capacity of certain cells. Such 
mechanisms include vitamin D as a negative regulator for renin and an inhibitor of cell proliferation 
and growth.  
4.1. Angiotensin-renin System 
Inappropriate activation of the renin-angiotensin system may represent a major risk factor for 
hypertension and, consequently, for cardiovascular diseases. Several studies have indicated that serum 
levels of 1,25(OH)2D3 are inversely associated with blood pressure or plasma renin activity in 
normotensive and hypertensive subjects [34-38]. In a experimental study with wild-type mice, the 
research group of Yan Chun Li [7] showed that inhibition of 1,25(OH)2D3 synthesis led to an increase 
in renin expression, whereas 1,25(OH)2D3 injection led to renin suppression in the juxtaglomerular 
apparatus, independently of parathyroid hormone and calcium metabolism [39]. The same group [40] 
also demonstrated, in cell cultures, that 1,25(OH)2D3 directly suppressed renin gene transcription by 
means of a VDR-dependent mechanism. Elucidating this mechanism, a study found that 1,25(OH)2D3 
suppressed renin gene expression in part by blocking the formation of the cyclic AMP response 
element [41]. These data suggest that vitamin D analogs and supplements may potentially be agents for 
controlling renin production and blood pressure. 
Corroborating this hypothesis, Fryer et al. [42] evaluated the effects of paricalcitol and calcitriol on 
renin expression in C57/BL6 mice and showed that paricalcitol produces significant dose-dependent 
reductions in renin/GAPDH expression and calcitriol produced renin suppression. Additionally, Zhou 
et al. [43] demonstrated regulation of the renin-angiotensin system through supplementation of 
1,25(OH)2D3 in 1-α hydroxylase knockout mice free of enzyme. 
4.2. Role of vitamin D in cardiac tissue 
Few in vitro and in vivo studies have evaluated the role of vitamin D in cardiac tissue. Carthy et al. 
[8], demonstrated in vitro that 1,25(OH)2D3 blocked the proliferation and growth of VSMC. In a recent 
study on administration of vitamin D analogs in cells cultures, Wu-Wong et al. [5] observed regulation 
of the expression of IGF1, Wilms tumor 1 and TGFß, which are three genes that are known to 
modulate cell proliferation. In addition, they observed downregulation of the expression of natriuretic 
peptide precursor B and thrombospondin 1, which inhibit cell proliferation. However, another study by 
the same group [44] suggested that elevated phosphorus affects VDR-mediated gene expression in 
human VSMC, and therefore the effect is not limited to VDR.  
Since VSMC is modulated by VDR, some studies have pointed towards its involvement in the 
endothelium. A study performed to evaluate endothelial function by brachial artery flow mediated 
dilatation in 23 asymptomatic vitamin D-deficient subjects found a positive correlation between 
endothelial function and 25(OH)D (r = 0.45; p = 0.001) [45].  
With regard to the action of vitamin D on cardiomyocytes, a study [46] confirmed the presence of 
VDR, and that 1,25(OH)2D3 affected the growth, proliferation and morphology of murine cardiac 
myocytes (HL-1 cells) in cultures. The cells were treated with 1,25(OH)2D3, and increased expression 
of myotrophin with decreasing expression of atrial natriuretic peptide and c-myc were observed. 
Furthermore, the 1,25(OH)2D3 treatment also increased the expression and nuclear localization of the Nutrients 2010, 2                                       
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VDR in these cardiomyocytes. Another study [47] showed that 1,25(OH)2D3 treatment in a model of 
hypertensive rats subjected to a high-salt diet resulted in lower heart weight, myocardial collagen 
levels, left ventricular diameter and cardiac output, thus suggesting that it had an important preventive 
role in relation to the development of cardiac hypertrophy and consequent congestive heart failure. 
Corroborating these findings, it was found that paricalcitol supplementation in Dahl salt-sensitive rats 
that were also fed a high-salt diet attenuated the cardiac hypertrophy [48]. In Sprague-Dawley rats, 
maternal vitamin D deficiency led to increased left ventricle volume, greater cardiomyocyte numbers 
and size, and a higher proportion of mononucleated cardiomyocytes in the offspring at four weeks of 
age [49].  
5. Vitamin D Supplementation Studies 
In 2009, Zittermann et al. [50] conducted a double-blind, placebo-controlled trial in which 12 
months of supplementation of 83.3µg of vitamin D was supplied to 200 women who had started a 
weight reduction program. They found that the group of supplemented women had greater decreases in 
PTH levels, triacylglycerides and tumor necrosis factor-α (TNF-α). Another important point was that 
weight loss did not differ between the vitamin D and placebo groups. Additionally, a study 
investigated whether vitamin D was associated with cytokine production [51]. It was found that 
vitamin D supplementation increased the anti-inflammatory cytokine production, such as IL-10, in 
patients with heart failure.  
A study on patients with predialysis chronic kidney disease showed that oral administration of 
alfacalcidol was associated with reduced risk of cardiovascular disease [52]. 
However, a randomized, double-blind, placebo-controlled trial on the population of the Women’s 
Health Initiative [53], which was administered 1,000 mg elemental calcium carbonate and 10µg of 
vitamin D3 daily, or placebo, found no reduction in mortality due to cardiovascular disease, but the 
hazard ratios trended in the direction of reduced risk. As an incidental finding, the daily amount of 
vitamin D3 in this study, like in other study using similar amounts of vitamin D supplementation [54], 
did not find any additional benefits. Furthermore, Bolland et al. [55] reported that calcium 
supplementation above the recommended levels in specific populations (elderly people or individuals 
with previous cardiovascular events) might increase the risk of cardiovascular events.  
In a double-blind, placebo-controlled study in 1987, Lind et al. [56] observed reductions in the 
blood pressure of 39 hypertensive patients with vitamin D supplementation. This reduction was also 
highlighted in another study on older women supplemented with calcium and vitamin D [57]. Another 
trial observed that administration of 1,25(OH)2D3 reduced blood pressure, as well as plasma renin 
activity and angiotensin II levels [58]. 
On the other hand, Thierry-Palmer et al. [59] increased the supply of vitamin D in the diet of salt-
sensitive rats that were administered a high-salt diet and observed an increase in serum 25(OH)D, but 
their hypertension was not alleviated. These findings could suggest that there is a potential difference 
in the effects on the vitamin D endocrine system between salt-induced hypertension and essential 
hypertension. 
Table 2 highlights the cardiovascular effects of vitamin D supplementation. 
 Nutrients 2010, 2                                       
 
 
432
Table 2. Cardiovascular effects of vitamin D supplementation. 
Study   Population  Supplementation 
type, dose and period 
Main outcomes 
Kimura et al.,  
1999 [58] 
Case report on a 42-year-
old man. 
Oral administration of 
0.2 μg of calcitriol 
È blood pressure, plasma 
renin activity and levels 
of angiotensin II. 
Pfeifer et al.,  
2001 [57] 
148 women 70 years of 
age or older (74 patients in 
calcium group and 74 
patients in vitamin-D-
calcium group). 
1,200 mg of CaCO3 or 
1,200 mg of CaCO3 + 
20 µg of 
cholecalciferol 
In vitamin-D-calcium 
group, Ç in 25(OH)D of 
72% and È in serum PTH 
of 17%, and in systolic 
blood pressure of 9.3%, 
heart rate È 5.4%.  
Schleithoff et al.,  
2006 [51] 
123 patients with 
congestive heart failure 
randomized into D(+) 
group and D(-) group 
D(+) group received 
50 µg of vitamin D3 + 
500 mg of Ca/d; D(-) 
group received 
placebo + 500 mg of 
Ca/d for 9 months 
In D(+) group: È PTH, 
Ç IL-10 and TNFα 
remained constant. 
In D(-) group: Ç TNFα. 
Survival rate did not 
differ significantly 
between groups. 
Zittermann et al.,  
2009 [50] 
200 women who started a 
weight-loss program (100 
patients in vitamin D 
group and 100 patients in 
placebo group). 
83.3 μg/d of 
cholecalciferol for 12 
months 
ÈPTH, triacylglycerides 
and TNF α. 
Sigiura et al.,  
2009 [52] 
665 patients with 
predialysis chronic kidney 
disease (107 patients in 
alfacalcidol treatment 
group and 558 in non-
treatment group). 
0.25–0.5 μg/d of 
alfacalcidol for 
24 weeks 
Lower incidence of 
cumulative cardiovascular 
events in alfacalcidol 
treatment group. 
LaCroix et al.,  
2009 [53] 
36,282 participants in 
Women’s Health Initiative 
(18,176 postmenopausal 
women in vitamin D group 
and 18,106 in placebo 
group). 
1,000 mg CaCO3 + 10 
µg/d of cholecalciferol 
for 7 years 
No reduction in 
cardiovascular mortality. 
6. Conclusion  
Hypovitaminosis D has been observed worldwide and several studies have demonstrated a strong 
association between vitamin D status and cardiovascular diseases. There are few food sources of 
vitamin D, and the lack of food fortification in some countries, associated with low cutaneous 
synthesis, intensifies vitamin D insufficiency. Moreover, the understanding of the exact mechanisms 
through which 25(OH)D or the active form 1,25(OH)2D3 regulate the renin-angiotensin system and 
cell proliferation and growth (such as VSMC and endothelium cells) remains incomplete. In this 
regard, identifying correct relationships between vitamin D status and cardiovascular disease is an Nutrients 2010, 2                                       
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important matter that could contribute towards prevention of such diseases. In the meanwhile, health 
professionals should be aware of the potential negative implications of vitamin D insufficiency and 
make recommendations for their patients to improve their vitamin D status. 
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